Pharmalot Ed Silverman The Supreme Court will review a contentious Amgen patent case, but not one involving Bristol. Why?
Pharmalot Ed Silverman After years of lax oversight, the NIH is starting to contact institutions about unreported clinical trial results
Pharmalot Ed Silverman A ‘blank check’: Bill to boost antibiotic development blasted as a ‘flawed’ giveaway to pharma
Pharmalot Ed Silverman A leaked version of a U.K.-India free trade deal sparks alarm over access to medicines
Biotech Jason Mast and Adam Feuerstein Novel solution to biotech’s market valuation woes: Just give the cash back
A STAT Investigation Jason Mast Death of patient in closely watched Alzheimer’s trial raises concern about risk for some groups
Biotech Brittany Trang Alphabet’s AI predicted the structure of 200 million proteins. Can it really speed up drug discovery?
Biotech Adam Feuerstein Arrowhead RNA treatment improves liver scarring in patients, but so does a placebo, clouding study results
Opinions+ Patricia Hurter Continuous manufacturing can help pharma companies save time, money, and more
Biotech Jason Mast Geron, biotech that once sparked talk of immortality, finally gets a (more modest) success
First Opinion Richard Marfuggi, Aparna Ahuja and Rick A. Bright Lessons learned from the deadly combination of sepsis and Covid-19
Biotech Jason Mast Drugmakers ask regulators to change standards on new Covid antibody drugs for most vulnerable
Biotech Jason Mast In bid to beat Bristol Myers, Takeda buys Nimbus’ anti-inflammatory drug for $4 billion
Pharmalot Ed Silverman Ongoing problems with a new European clinical trial registry could cause ‘catastrophe’
Pharmalot Ed Silverman Cambodia halts exports of non-human primates, threatening drug discovery efforts
Biotech Matthew Herper and Allison DeAngelis ‘This is not a cure’: Consensus begins to emerge on new Alzheimer’s drug
First Opinion Arthur L. Caplan and Kenneth I. Moch Breakthrough Therapies Act: Good idea, wrong solution
In the Lab Megan Molteni On the long road to treating Huntington’s genetic stutter, scientists return to overlooked clues
Biotech Jonathan Wosen Vertex revolutionized cystic fibrosis treatment. Its executives say that’s just the start
Biotech Adam Feuerstein, Jason Mast and Damian Garde ‘We were right all along:’ For Japanese drugmaker Eisai, success against Alzheimer’s has been a long time coming
Health Eleanor Cummins After decades of setbacks, scientists make strides toward the holy grail of male birth control
Pharmalot Ed Silverman More drugmakers are expanding access in poorer countries, but progress continues to lag overall
Health Andrew Joseph and Jason Mast U.S. set to face third Covid winter, this time without key tools and treatments